Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 2:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2977–3000 of 185,080 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: NOT program Clear all

Conditions: Hemophilia A
Interventions: rFVIIIFc; Biological
Lead sponsor: Bioverativ, a Sanofi company; Industry
Eligibility: Up to 5 Years · Male only
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 20
States / cities: Little Rock, Arkansas • Duarte, California • Sacramento, California + 16 more

Conditions: Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Liver Cancer, Neuroblastoma, Ovarian Cancer, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: ABT-751; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: Up to 18 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2010
U.S. locations: 3
States / cities: Chicago, Illinois • Bethesda, Maryland • Philadelphia, Pennsylvania

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Smac mimetic TL32711, gemcitabine hydrochloride, laboratory biomarker analysis, pharmacological study, biopsy; Drug · Other · Procedure
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 2
States / cities: Buffalo, New York • Philadelphia, Pennsylvania

Conditions: HPV16+ Squamous Cell Carcinoma
Interventions: HB-200; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: PR610; Drug
Lead sponsor: Proacta, Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 4
States / cities: Scottsdale, Arizona • Sacramento, California • Chicago, Illinois + 1 more

Conditions: HIV (Human Immunodeficiency Virus)
Interventions: MGD020, MGD014, Vorinostat, Temporary treatment interruption; Drug · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Breast Cancer, Cognitive/Functional Effects, Fatigue, Long-term Effects Secondary to Cancer Therapy in Adults
Interventions: assessment of therapy complications, cognitive assessment, fatigue assessment and management; Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 2
States / cities: Cleveland, Ohio

Conditions: Actinic Keratoses
Interventions: Antihistamine Cetirizine Hydrochloride, Placebo; Drug · Other
Lead sponsor: Goldman, Butterwick, Fitzpatrick and Groff; Other
Eligibility: 19 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: San Diego, California

Conditions: Thoracic Aorta Dilatation
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 35 Years and older
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Glucose Metabolism Disorders, Hunger, Fat Burn
Interventions: Carbohydrate-first meal, Carbohydrate-last meal; Other
Lead sponsor: Old Dominion University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Hypoxia
Interventions: Pulse Oximeter; Device
Lead sponsor: Nihon Kohden; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Breast Cancer
Interventions: Ipatasertib, Placebo, Palbociclib, Fulvestrant; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 5
States / cities: Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 1 more

Conditions: Breast Cancer, Perioperative/Postoperative Complications
Interventions: patient interviewing to obtain menstrual history, blood sampling; Behavioral · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 1,118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2009
U.S. locations: 52
States / cities: Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 44 more

Conditions: COPD, Dyspnea
Interventions: Pulmonary Rehabilitation; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 40 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Carpal Tunnel Syndrome
Interventions: Kinesiology Tape; Device
Lead sponsor: University of Nevada, Las Vegas; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Pancreatic Ductal Adenocarcinoma
Interventions: OT-101, mFOLFIRINOX; Drug
Lead sponsor: Oncotelic Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 455 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Detroit, Michigan • Houston, Texas

Conditions: Ulcerative Colitis
Interventions: Mirikizumab IV, Mirikizumab SC; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 6
States / cities: San Francisco, California • Atlanta, Georgia • Indianapolis, Indiana + 3 more

Conditions: Neovascular Age-related Macular Degeneration
Interventions: CLS-AX; Drug
Lead sponsor: Clearside Biomedical, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 7
States / cities: Phoenix, Arizona • Mountain View, California • Sacramento, California + 4 more

Conditions: Epidemic Kaposi's Sarcoma, Recurrent Kaposi's Sarcoma
Interventions: interleukin-12; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Timeline: 1997 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: Multispectral Optoacoustic Tomography, Temperature Measurement; Device · Procedure
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Lichen Sclerosus
Interventions: Delgocitinib, Cream Vehicle; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 652 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 20
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 16 more

Conditions: Amyloidosis
Interventions: Idelalisib; Drug
Lead sponsor: John Mark Sloan; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Major Depressive Disorder
Interventions: Trazodone Hydrochloride (HCl) Extended-Release Tablets, Placebo; Drug
Lead sponsor: Labopharm Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 412 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 28
States / cities: Birmingham, Alabama • Mesa, Arizona • Beverly Hills, California + 25 more

Conditions: Sepsis, Community Acquired Pneumonia (CAP)
Interventions: OPT101, Placebo; Drug · Other
Lead sponsor: Op-T LLC; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Denver, Colorado

Search by objective public record fields.

An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Previously Untreated Males With Severe Hemophilia A

ABT-751 in Treating Young Patients With Refractory Solid Tumors

Gemcitabine Hydrochloride and Smac Mimetic TL32711 in Treating Patients With Advanced Solid Tumors

A Study of HB-202/HB-201 in People With Human Papilloma Virus 16-Positive Head and Neck Squamous Cell Cancer (HPV 16+ HNSCC)

A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors

The DART DELIVER-02 Study

Fatigue Caused by Chemotherapy in Women Who Have Undergone Surgery for Breast Cancer and in Healthy Volunteers

A Clinical Trial Evaluating the Role of Systemic Antihistamine Therapy in the Reduction of Adverse Effects Associated With Topical 5-aminolevulinic Acid Photodynamic Therapy

A Study of High-intensity Strength Training and Thoracic Aorta Dilatation

Food Orders on Blood Glucose and Fuel Use at Rest

Accuracy of Pulse Oximeters With Profound Hypoxia At Rest (NIHO17)

A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer

Correlation of Menstrual Cycle Phase at Time of Primary Surgery With 5-Year Disease-Free Survival in Women With Stage I or Stage II Breast Cancer

Making Sense of Dyspnea Assessment

Efficacy of Red Kinesiology Tape on Carpal Tunnel-Like Symptoms and Performance in Esports Gamers

A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis

Extension Study to Evaluate the Long-term Outcomes of Subjects in the CLS-AX CLS1002-101 Study

Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma

Multispectral Optoacoustic Tomography in Head and Neck Squamous Cell Cancer

A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen Sclerosus

Idelalisib for Immunoglobulin M (IgM)-Associated Primary (AL) Amyloidosis

A Randomized, Double-blind, Two-arm Study Comparing the Efficacy and Safety of Trazodone Contramid® OAD and Placebo in the Treatment of Unipolar Major Depressive Disorder.

OPT101 in Patients With Community Acquired Pneumonia (CAP) With Sepsis